ClinicalTrials.gg
CompletedNCT00440037Updated Jan 21, 2020Results posted

Open Label Extension Study of AMG 531 in Japanese Subjects With ITP

A Phase 2/3 interventional study of AMG 531 in Immune (Idiopathic) Thrombocytopenic Purpura (ITP), sponsored by Kyowa Kirin Co., Ltd.. Completed at 13 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-01-21.

Sponsored by Kyowa Kirin Co., Ltd. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing romiplostim in Purpura, Thrombocytopenic — 1 open to participants now, 1 under way, none of them phase 3. romiplostim · Purpura, Thrombocytopenic.

Enrollment
8th of 11
44 · median 62
Started
2006
with 2 others
Phase 2/3
Only one
of the 11
Registered
7th of 11
by date
Lead sponsor
2 of 11
Kyowa Kirin Co., Ltd.

Among the 11 studies testing romiplostim in Purpura, Thrombocytopenic, this one is the 8th largest by enrollment, is one of 3 that started in 2006, is the only one in phase 2/3, and was the 7th registered.

Purpura, Thrombocytopenic

32 studies on the registry are indexed under Purpura, Thrombocytopenic; 6 are open to participants now.

Browse Purpura, Thrombocytopenic studies →

Open to participants now

1 of the 11 studies testing romiplostim in Purpura, Thrombocytopenic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About romiplostim

romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 4 Purpura, Thrombocytopenic studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing romiplostim in Purpura, Thrombocytopenic, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of long term dosing of AMG 531 in thrombocytopenic Japanese subjects with ITP.

It is anticipated that AMG 531 will be a safe and well tolerated in long term treatment and that AMG 531 will effectively raise and maintain platelet counts to a desired therapeutic range, when individual dose adjustments based on platelet counts are permitted.

This study is available to subjects who have completed any previous AMG 531 ITP study in Japan and meet the eligibility criteria of this study.

Read the detailed description

Romiplostim was administered by subcutaneous (SC) injection once per week. If subjects entered the extension study within 12 weeks from the last investigational product administration in the previous study and had shown an increase in platelet counts ≥ 20 x 109/L from baseline at least once during the 13-week treatment period (excluding 4 weeks after receiving rescue medication), they were treated with romiplostim at the same weekly dose (last dose on study) received in the previous study. Otherwise, subjects were treated with romiplostim at a starting dose of 3 μg/kg. Dose adjustment based on platelet counts was allowed throughout the treatment period to allow subjects to maintain platelet counts in the target range of ≥ 50 to ≤ 200 x 109/L, up to a maximum permitted dose of 10 μg/kg.

03

Conditions studied

  • Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Keywords

  • AMG 531
  • ITP
  • Long term treatment
  • Japanese
  • Romiplostim
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have previously completed an AMG 531 ITP study in Japan.
  • count taken at the screening visit must be \< 50 x 109/L.
  • Before any study-specific procedure, the appropriate written must be obtained.

Exclusion criteria

Exclusion Criteria

  • Any significant change in medical history since completion of the previous AMG 531 ITP study including bone marrow stem cell disorders or new active
  • known positive result from a test for neutralizing antibodies to AMG 531 in the previous AMG 531 ITP study
  • Currently receiving any treatment for ITP except oral , azathioprine and/or danazol administered at a constant dose and schedule from at least 4 weeks prior to the screening visit
  • received intravenous immunoglobulin, anti-D immunoglobulin, or any drug administered to increase counts (eg, etc) within 1 week before the screening visit
  • received anti-malignancy agents (eg, cyclophosphamide, 6-mercaptopurine, vincristine, vinblastine, Interferon-alfa etc) within 4 weeks before the screening visit
  • received any monoclonal antibody drugs (eg, rituximab etc) within 8 weeks before the screening visit
  • Less than 4 weeks since receipt of any therapeutic drug or device that is not Ministry of Health, Labor and Welfare (MHLW) approved for any indication before the screening visit (excluding AMG 531)
  • Pregnant or breast feeding
  • Subjects of who are not using adequate precautions, in the judgment of the investigator
  • known severe drug
  • Concerns for subject's compliance with the protocol
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    AMG 531

    Biological: AMG 531

Interventions

  • BiologicalAMG 531

    AMG 531 will be administered by SC injection once per week from Week 1 (Day 1). The maximum permitted dose of AMG 531 is 10 μg/kg. AMG 531 will be supplied as a sterile, white, preservative-free, lyophilized powder in 5 mL glass vials containing 0.6 mg of protein per vial, and a protein concentration of 0.5 mg/mL when reconstituted with 1.2 mL of sterile water for injection.

    Also known as: Romiplostim

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events Including Clinically Significant Changes in Laboratory Values.

    Subjects who reported at least 1 adverse event after beginning treatment with romiplostim in this study

    Time frame: Through study completion, the median treatment duration (time between first dose and last dose) was 146.0 weeks (range: 12 to 243 weeks)

Secondary outcomes

  1. Incidence of Anti AMG 531 Antibody Formation

    Subjects with positive anti-AMG 531 antibodies (either to the peptide portion of AMG 531 or to the intact molecule) and antibodies that cross-react with endogenous thrombopoietin (TPO)

    Time frame: Through study completion, the median treatment duration (time between first dose and last dose) was 146.0 weeks (range: 12 to 243 weeks)

  2. Incidence of Platelet Response (Platelet Response is Defined as a Doubling of Baseline Platelet Counts and More Than 50 x 10^9/L; Baseline Platelet Counts is That Obtained in the Previous Study)

    Time frame: Through study completion, the median treatment duration (time between first dose and last dose) was 146.0 weeks (range: 12 to 243 weeks)

  3. Percentage of Subjects Able to Reduce or Discontinue Their Concurrent ITP Therapies (for Subjects That Are Receiving Oral Corticosteroids at a Constant Dose and Schedule at the Screening Visit)

    Time frame: Through study completion, the median treatment duration (time between first dose and last dose) was 146.0 weeks (range: 12 to 243 weeks)

  4. Change From Baseline in Patient-reported Outcome (PRO) Endpoints at Each Time Point (Baseline PRO is Obtained at Day 1 Predose)

    Short Form 36 (SF-36): The SF-36 has 36 questions with 8 domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health. In addition to deriving a score for each of the domains, the SF-36 generates 2 summary scores: a physical component summary (PCS) and a mental component summary (MCS). These 8 domains and 2 summary scores are scored from 0 to 100, with higher scores indicating better health status. The official version in Japanese was used in this study. Euroqol-5 Dimensions (EQ-5D): The EQ-5D is a patient-completed, multidimensional measure of HRQOL. EQ-5D index values range from -0.59 to 1.00. The EQ-5D visual analogue scale (VAS) records the respondents' self-rated health status on a vertical graduated (0 to 100) visual analogue scale. Higher EQ-5D Index and VAS scores represent better health status. The official version in Japanese was used in this study.

    Time frame: By Week 48

07

Results

Posted Jan 21, 2020

Participant flow

Subjects who had completed any previous romiplostim ITP study in Japan (Studies 20050162/NCT00305435 or 20060216/NCT00603642) were eligible to screen for this study. The study began in October 2006 and continued until romiplostim was commercially available in Japan.

Participant flow — Overall Study
MilestoneAMG 531
Started44
Completed35
Not completed9
Withdrew: Withdrawal by subject6
Withdrew: Administrative decision3

Outcome measures

PrimaryPercentage of Participants With Adverse Events Including Clinically Significant Changes in Laboratory Values.

Subjects who reported at least 1 adverse event after beginning treatment with romiplostim in this study

Time frame:
Through study completion, the median treatment duration (time between first dose and last dose) was 146.0 weeks (range: 12 to 243 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events Including Clinically Significant Changes in Laboratory Values.
percentage of participantsAMG 531
Percentage of Participants With Adverse Events Including Clinically Significant Changes in Laboratory Values.100
SecondaryIncidence of Anti AMG 531 Antibody Formation

Subjects with positive anti-AMG 531 antibodies (either to the peptide portion of AMG 531 or to the intact molecule) and antibodies that cross-react with endogenous thrombopoietin (TPO)

Time frame:
Through study completion, the median treatment duration (time between first dose and last dose) was 146.0 weeks (range: 12 to 243 weeks)
Reported as:
Number · percentage of participants
Incidence of Anti AMG 531 Antibody Formation
percentage of participantsAMG 531
Positive for romiplostim-neutralizing antibodies0
Positive for TPO-neutralizing antibodies0
SecondaryIncidence of Platelet Response (Platelet Response is Defined as a Doubling of Baseline Platelet Counts and More Than 50 x 10^9/L; Baseline Platelet Counts is That Obtained in the Previous Study)
Time frame:
Through study completion, the median treatment duration (time between first dose and last dose) was 146.0 weeks (range: 12 to 243 weeks)
Reported as:
Number · percentage of participants
Incidence of Platelet Response (Platelet Response is Defined as a Doubling of Baseline Platelet Counts and More Than 50 x 10^9/L; Baseline Platelet Counts is That Obtained in the Previous Study)
percentage of participantsAMG 531
Incidence of Platelet Response (Platelet Response is Defined as a Doubling of Baseline Platelet Counts and More Than 50 x 10^9/L; Baseline Platelet Counts is That Obtained in the Previous Study)95.5 (84.5 to 99.4)
SecondaryPercentage of Subjects Able to Reduce or Discontinue Their Concurrent ITP Therapies (for Subjects That Are Receiving Oral Corticosteroids at a Constant Dose and Schedule at the Screening Visit)
Time frame:
Through study completion, the median treatment duration (time between first dose and last dose) was 146.0 weeks (range: 12 to 243 weeks)
Reported as:
Number · percentage of participants
Percentage of Subjects Able to Reduce or Discontinue Their Concurrent ITP Therapies (for Subjects That Are Receiving Oral Corticosteroids at a Constant Dose and Schedule at the Screening Visit)
percentage of participantsAMG 531
Percentage of Subjects Able to Reduce or Discontinue Their Concurrent ITP Therapies (for Subjects That Are Receiving Oral Corticosteroids at a Constant Dose and Schedule at the Screening Visit)100
SecondaryChange From Baseline in Patient-reported Outcome (PRO) Endpoints at Each Time Point (Baseline PRO is Obtained at Day 1 Predose)

Short Form 36 (SF-36): The SF-36 has 36 questions with 8 domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health. In addition to deriving a score for each of the domains, the SF-36 generates 2 summary scores: a physical component summary (PCS) and a mental component summary (MCS). These 8 domains and 2 summary scores are scored from 0 to 100, with higher scores indicating better health status. The official version in Japanese was used in this study. Euroqol-5 Dimensions (EQ-5D): The EQ-5D is a patient-completed, multidimensional measure of HRQOL. EQ-5D index values range from -0.59 to 1.00. The EQ-5D visual analogue scale (VAS) records the respondents' self-rated health status on a vertical graduated (0 to 100) visual analogue scale. Higher EQ-5D Index and VAS scores represent better health status. The official version in Japanese was used in this study.

Time frame:
By Week 48
Reported as:
Mean · score on a scale
Change From Baseline in Patient-reported Outcome (PRO) Endpoints at Each Time Point (Baseline PRO is Obtained at Day 1 Predose)
score on a scaleAMG 531
Change in EQ-5D Index score at Week 480.02 ± 0.12
Change in EQ-5D VAS score at Week 486.13 ± 16.48
Change in SF-36 physical functioning at Week 480.68 ± 7.19
Change in SF-36 role physical at Week 482.30 ± 10.43
Change in SF-36 bodily pain at Week 48-0.87 ± 13.42
Change in SF-36 General Health Perception at W481.30 ± 5.14
Change in SF-36 Vitality at Week 481.12 ± 8.42
Change in SF-36 Social Functioning at Week 481.22 ± 8.56
Change in SF-36 Role Emotional at Week 481.84 ± 12.82
Change in SF-36 Mental Health at Week 48-1.42 ± 9.04
Change in SF-36 Physical Component at Week 481.13 ± 6.85
Change in SF-36 Mental Component at Week 480.33 ± 9.19

Adverse events

Collected over The duration of treatment in this study ranged from 12 to 243 weeks; the median (Q1, Q3) duration of treatment in this study was 146.0 (119.5, 166.0) weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AMG 5310/44 (0%)12/44 (27.3%)44/44 (100%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventAMG 531
Haemorrhagic AnaemiaBlood and lymphatic system disorders1/44
ThrombocytopeniaBlood and lymphatic system disorders1/44
ArrhythmiaCardiac disorders1/44
Colonic polypGastrointestinal disorders1/44
MelaenaGastrointestinal disorders1/44
Mouth HaemorrhageGastrointestinal disorders1/44
Feeling AbnormalGeneral disorders1/44
PyrexiaGeneral disorders1/44
CholelithiasisHepatobiliary disorders1/44
AppendicitisInfections and infestations1/44
Most frequent other events
Showing 10 of 52
Most frequent other events
EventAMG 531
NasopharyngitisInfections and infestations35/44
HeadacheNervous system disorders19/44
Back PainMusculoskeletal and connective tissue disorders12/44
ContusionInjury, poisoning and procedural complications9/44
VertigoEar and labyrinth disorders8/44
Abdominal Pain UpperGastrointestinal disorders8/44
MalaiseGeneral disorders8/44
ArthralgiaMusculoskeletal and connective tissue disorders8/44
Pain In ExtremityMusculoskeletal and connective tissue disorders8/44
DiarrhoeaGastrointestinal disorders7/44

Baseline characteristics

Age, Continuous
Age, Continuous(years)AMG 531
Mean54.9 ± 12.9
Sex: Female, Male
Sex: Female, Male(Participants)AMG 531
Female31
Male13
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AMG 531
American Indian or Alaska Native0
Asian44
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)AMG 531
Japan44
08

Study locations

13 sites
  • Research Site
    Sapporo, Hokkaido 060-8648, Japan
  • Research Site
    Tsukuba, Ibaraki 305-8576, Japan
  • Research Site
    Isehara-shi, Kanagawa 259-1193, Japan
  • Research Site
    Sagamihara, Kanagawa 228-8555, Japan
  • Research Site
    Suita, Osaka 565-0871, Japan
  • Research Site
    Chuo, 409-3898, Japan
  • Research Site
    Hirakata, 573-1191, Japan
  • Research Site
    Hiroshima, 730-8619, Japan
  • Research Site
    Kumamoto, 860-8556, Japan
  • Research Site
    Moriguchi, 570-8507, Japan
  • Research Site
    Tokyo, 113-8655, Japan
  • Research Site
    Tokyo, 141-8625, Japan
  • Research Site
    Tokyo, 160-8585, Japan
09

References and documents

Publications

  • Arranz R, Garcia-Noblejas A, Grande C, Cannata-Ortiz J, Sanchez JJ, Garcia-Marco JA, Alaez C, Perez-Calvo J, Martinez-Sanchez P, Sanchez-Gonzalez B, Canales MA, Conde E, Martin A, Arranz E, Terol MJ, Salar A, Caballero D. First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group. Haematologica. 2013 Oct;98(10):1563-70. doi: 10.3324/haematol.2013.088377. Epub 2013 Jun 10. PubMed 23753021 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Jul 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2020, 8 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2007
First posted
Feb 26, 2007
Start
Nov 2006
Primary completionActual
Jul 2011
CompletionActual
Sep 2011
Results first posted
Jan 21, 2020
Last update
Jan 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00440037
Responsible party
Sponsor
First posted
Feb 26, 2007
Start date
Nov 2006
Primary completion
Jul 2011
Completion
Sep 2011
Results posted
Jan 21, 2020
Last update
Jan 21, 2020

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romiplostim

Start the discussion